figshare
Browse
12885_2022_9243_MOESM1_ESM.doc (220 kB)

Additional file 1 of Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

Download (220 kB)
journal contribution
posted on 2022-02-02, 04:32 authored by Daniil L. Stroyakovskiy, Natalya V. Fadeeva, Marina P. Matrosova, Konstantin G. Shelepen, Grigoriy A. Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy D. Voevodin, Mariya S. Shustova, Fedor Kryukov
Additional file 1.

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    overall response ratesoverall response ratecell lung cancer47 %; 11unexpected adverse reactions6 %; 131referent bevacizumab drugstudy number nct01763645primary study endpointtotal 357 patientsrandomly assigned 3reference group ).reference bevacizumab groupbevacizumab biosimilar bcdreference bevacizumabbevacizumab biosimilaradverse events6 cyclesnsclc ).biosimilar bcd2013 ).bevacizumab antibodiesstudy goalwide panelunbearable toxicitytherapy continuedsquamous nsclcsquamous nonshort liferegistration 09randomized doubleprevious treatmentpreclinical studiesphysicochemical studiespharmacokinetics assessmentoutcome measuresmethods patientsline treatmentequivalence marginsconclusions thusadvanced non[- 996 %)73 %].65 %).09 %].022 group021 group

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC